Abstract: A method for processing game information, including: obtaining a target disease in a game of a virtual city, where the target disease comprises at least one disease in a disease database; determining a current transmission target disease in the virtual city according to a trigger probability and a trigger interval of the target disease, where the current transmission target disease is set to transmit in the virtual city at a preset rate; displaying a crisis early warning task corresponding to the current transmission target disease on the graphical user interface, where the crisis early warning task includes a disease name of the current transmission target disease and corresponding task information; and reducing, in response to completing the task information, the preset rate of transmission of the current transmission target disease in the virtual city.

Abstract: An in-game virtual object control method including: providing, by a first terminal, a virtual object residence area on a graphical user interface of the first terminal, where a plurality of virtual objects to be selected are displayed in the virtual object resident area according to a trigger instruction; in response to a selection instruction for the plurality of virtual objects to be selected, selecting a target number of target virtual objects from the plurality of virtual objects to be selected, and adding the target number of target virtual objects into a virtual city; generating a demand task associated with at least one unselected virtual object to be selected, and displaying, on the graphical user interface, task information corresponding to the demand task; and completing the demand task, increasing the a preset duration for the virtual object to be selected to leave the virtual object residence area corresponding to the demand task.

Abstract: 1,5-dihydro-2,4-benzodiazepine-3-one derivatives, such as a compound represented by formula I, acts on 5-HT2A and 5-HT2C receptors. The selectivity for 5-HT2A is superior or similar to pimavanserin. The derivative is used for treating schizophrenia or Parkinson’s disease, dementia-related behavioral disorders, and psychosis. The antipsychotic activity of the compound is equivalent to that of pimavanserin, the side effects of sedation and and worsening of exercise are less than those of pimavanserin, and cardiotoxicity is less than that of pimavanserin.